


Searching News Database: INS-20
HSMN NewsFeed - 12 Feb 2009
Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
Additional items found! 1
Members Archive contains
1 additional stories matching:
INS-20
(Password required)
INS-20
(Password required)
